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ABSTRACT
Radiation recall is an acute inflammatory reaction con-
fined to previously irradiated areas that can be trig-
gered when chemotherapy agents are administered
afterradiotherapy.Itremainsapoorlyunderstoodphe-
nomenon, but increased awareness may aid early diag-
nosis and appropriate management. A diverse range of
drugs used in the treatment of cancer has been associ-
ated with radiation recall. As most data come from case
reports, it is not possible to determine the true inci-
dence,buttodatetheantineoplasticdrugsforwhichra-
diation recall reactions have been most commonly
reported include the anthracycline doxorubicin, the
taxanes docetaxel and paclitaxel, and the antimetabo-
lites gemcitabine and capecitabine. Radiation recall is
drug-specific for any individual patient; it is not possi-
ble to predict which patients will react to which drugs,
and rechallenge does not uniformly induce a reaction.
There are no identifiable characteristics of drugs that
causeradiationrecall,andthus,itisapossibilitythatmust
be kept in mind with use of any drug after radiotherapy,
including those from new drug classes. Although it is not
yet possible to design treatment regimens to eliminate the
risk of radiation recall, it seems likely that risks can be
minimized by prolonging the interval between completion
of radiotherapy and initiation of chemotherapy. The On-
cologist 2010;15:1227–1237
INTRODUCTION
Treatment of cancer involves the widespread use of radio-
therapy in conjunction with chemotherapy. Both treatment
paradigms are associated with well-described, but not al-
ways overlapping, profiles of tolerability. Although giving
chemotherapyafterradiotherapycanbevaluableclinically,
it can also induce the phenomenon of radiation recall.
Radiation recall is an uncommon and unpredictable
phenomenon. It is characterized by an acute inflammatory
reaction confined to previously irradiated areas that is trig-
geredbytheadministrationofprecipitatingsystemicagents
after radiation treatment [1–4]. The most commonly impli-
cated drugs are anticancer agents, but other drugs can also
cause radiation recall, including some antibiotics, antitu-
berculosis drugs, and simvastatin [1, 3].
It is helpful to differentiate between radiation recall and
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in the days after irradiation when reaction to systemically
administered drugs is common, and if the time interval be-
tween end of radiation and chemotherapy is 7 days, such
reactions can be considered radiation enhancement or sen-
sitization. It has been suggested that radiation recall should
be differentiated by a later occurrence after completion of
radiotherapy (e.g., 7 days) [3]. Radiation recall is much
less common clinically than radiosensitization. It can occur
monthsorevenmanyyearsafterirradiation,suggestingthat
the mechanisms may be different from those of radiosensi-
tization [3], although others have suggested that radiation
recall is a form of delayed radiosensitization [4].
First described in 1959 [5], radiation recall remains a
poorly understood phenomenon. The aim of this review is
to provide an overview of the clinical presentation and
treatment of radiation recall within the context of cancer
management, including updated information on reactions
reported with the newest anticancer agents. A detailed case
study of the first reported case of radiation recall with ixa-
bepilone (BMS-247550; Bristol-Myers Squibb, New
York), the first of a new class of antineoplastic agents the
epothilones, is included.
INCIDENCE OF RADIATION RECALL
Few systematic reports have examined the incidence of ra-
diation recall, and most of the literature concerning this
phenomenon is presented as case reports, limiting the op-
portunity to determine the actuarial risk of occurrence.
Radiationrecallwasreportedin8.8%ofpatientsreceiv-
ing a range of chemotherapeutic agents after completion of
radiotherapyinanobservationalstudyof91patientsunder-
goingpalliativetreatmentformetastaticdisease(Fig.1)[6].
The time interval between the completion of radiation ther-
apy and the administration of cytotoxic chemotherapy was
between 6 and 37 days in patients in whom radiation recall
developed[6].Inlinewiththeexpectedincidence,noagent
administered to less than five patients in this study elicited
a radiation recall reaction. Cisplatin (n  10) was the only
drug taken by more than five patients that did not cause a
radiation recall reaction. In the American Society of Breast
Surgeons MammoSite Breast Brachytherapy Registry
Trial, 148 patients received chemotherapy within 90 days
ofacceleratedpartialbreastirradiation(34Gy)[7].Chemo-
therapyincludeddoxorubicinin75%ofcases.Duringafol-
low-up of 1 year, radiation recall occurred in 15 patients
(11.5% of 131 evaluable patients).
Otherstudieshavesuggestedincidencesofradiationre-
call 6% among patients receiving systemic therapy after
previousradiationexposure.Oneof20patientstreatedwith
capecitabine 4 weeks after previous combination therapy
with capecitabine and radiotherapy developed radiation re-
call[8].Among32patientstreatedwithdocetaxel(8mono-
therapy and 24 combination therapy), 2 patients (6%)
Figure 1. Frequency of radiation recall reactions in patients given chemotherapy within 6 months of radiotherapy in an obser-
vational study (91 patients). In total, 8 patients experienced radiation recall. Adapted from Kodym E, Kalinska R, Ehringfeld C et
al. Frequency of radiation recall dermatitis in adult cancer patients. Onkologie 2005;28:18–21, with permission.
Abbreviations: 5-FU, 5-fluorouracil; CAP, capecitabine; CIS, cisplatin; CYC, cyclophosphamide; DOC, docetaxel; EPI, epi-
rubicin; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; GEM, gemcitabine; MEL, melphalan; mono, monotherapy;
TRZ, trastuzumab; VIN, vinorelbine.
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spective review of 171 patients who had previously re-
ceived radiotherapy and subsequently received docetaxel,
1.8% developed radiation recall (3 patients were affected)
[9].
PATHOPHYSIOLOGY OF RADIATION RECALL
The pathophysiological basis of cutaneous radiation recall
is not known. Several hypotheses have been proposed, but
arenotyetsupportedbyadequateevidencetobeconsidered
proven [1, 3, 4, 10, 11].
Given that reaction recall reactions are drug-specific
and differ between individuals, it is unlikely that the cyto-
toxic or other pharmacological activities of anticancer
drugs are solely responsible. Theories involving depletion
and/or changes in function of stem cells in the irradiated
area are difficult to reconcile with the unpredictable nature
ofradiationrecall,thesometimesveryrapidonsetofaction,
and the fact that reactions are not uniformly elicited with
rechallenge. It is possible that stem cells in the irradiated
area have increased sensitivity, or display a “remembered”
reaction, to subsequent chemotherapy [1, 3, 4].
Camidge and Price have proposed that cutaneous radi-
ation recall reactions are caused by idiosyncratic drug hy-
persensitivityreactionsthatmaybeanalogoustofixeddrug
eruptions [3]. This localized hypersensitivity likely in-
volves direct activation of nonimmune inflammatory path-
ways; irradiation lowers the inflammatory response
threshold. It has been suggested that this mechanism could
bemediatedbycontinuedlow-levelsecretionoftheinflam-
mation-mediating cytokines induced by radiation. The
presence of a precipitating chemotherapy agent may then
upregulate these cytokines, resulting in a radiation recall
reaction [1].
Keratinocyte necrosis, related to cumulative direct
DNA damage and oxidative stress, could play a major role
inradiationrecalldermatitis[11].Specimensfromeightpa-
tients with radiation recall dermatitis showed ballooning
degeneration of epidermal keratinocytes with a mixed in-
flammatory infiltrate [11]. Underlying nutritional deficits
were also identified, which may contribute to the process
because of endogenous scavenger systems becoming
depleted.
In the case of capecitabine, it has been suggested that
radiation recall may result from upregulation of thymidine
phosphorylase, which could induce angiogenesis in the ra-
diated area and local prodrug activation. Capecitabine is a
prodrug that is converted to the active agent fluorouracil
[8, 12].
PRESENTATION OF RADIATION RECALL
One of the important features of radiation recall is that the
reaction affects skin (or other organs) that was previously
quiescent and apparently normal. The area affected clearly
correspondstoanareapreviouslyirradiated,althoughinthe
case of skin reactions the local effect may occasionally
spread or become generalized [3]. It should be differenti-
ated from incomplete healing of ongoing skin reactions to
theradiationitself.Patientswhoexperienceradiationrecall
reactions may or may not have experienced acute radiation
reactions. Many patients who develop radiation recall have
no reaction to radiation during or at the end of radiotherapy
[1, 3, 13].
The time interval between end of radiation therapy and
administration of the precipitating chemotherapy varies
widely in cases of radiation recall (Table 1). Camidge and
Price [3] advocate that the reaction should be considered to
be radiation recall only if the time lag is 7 days. They cal-
culatedthemedianintervaltobe40daysforradiationrecall
dermatitis linked to any systemic drugs [3]. However, there
are several reports of radiation recall occurring years after
completion of radiation treatment (Table 1). For example,
one radiation recall reaction of ulcerative stomatitis was
triggered by doxorubicin 15 years after radiotherapy [14].
In another patient, radiation recall dermatitis was triggered
by pemetrexed when given 25 years after radiotherapy, and
the reaction occurred again on rechallenge [15].
The onset of the symptoms of radiation recall usually
occurswithindaystoafewweeksafterexposuretothepre-
cipitatingchemotherapydrug,frequentlyafterthefirstdose
and sometimes during or immediately after intravenous ad-
ministration (Table 1). Less commonly, reactions become
evident over a few months after oral administration [1, 3].
Radiation recall reactions most commonly present on
the skin, with skin reactions comprising around two thirds
of cases (Table 1). Radiation recall dermatitis is usually of
mild or moderate intensity, but can be severe in some in-
stances (10%) [3]. Depending on severity, cutaneous ra-
diation recall may be characterized by one or more
dermatologic symptoms that can range from mild rash, dry
desquamation and/or pruritus, to symptoms that are in-
creasingly painful and may include swelling/edema, vesi-
cles, maculopapular eruptions, and papules. In the most
severe cases, ulceration and skin necrosis can occur [1, 3,
4]. The characteristic histopathological finding is a mixed
nonspecific inflammatory infiltrate [1, 11].
U.S. National Cancer Institute Common Terminology
CriteriaforAdverseEvents(CTCAE)cangradeseverityof
radiation recall dermatitis. Radiation recall was previously
listed separately in the CTCAE, but in the most recent ver-
sion (v.3), it is merged into the category “Rash: dermatitis
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1 wk after completion of radiation therapy unless otherwise stated
Drug
No. of
cases
Radiation
dose (Gy)
Time interval
between radiation
and chemotherapy
Time to onset
after
chemotherapy Reaction References
Bevacizumab 
gemcitabine
a 1 NR NR NR Gastritis with gastric and
vaginal bleeding
22
Bleomycin 10 mg/m
2 1 40 8 day(s) 3 day(s) after 2nd
dose
Mild skin reaction 35
Capecitabine 1000 mg/m
2
or 2000 mg bid  14
7 30–50.4
b 13–28 day(s)
b 3 day(s) to 2 mo(s)
or during 2nd
Mild to moderate skin
reaction (4)
6, 8, 12,
38
days
b cycle
b Diffuse gastritis and/or
duodenitis (3)
Capecitabine and
docetaxel
1 NR 27 day(s) NR Moderate skin reaction 6
Cisplatin 1 NR 1 yr NR Skin reaction 11
Cisplatin, epirubicin, and
mitomycin
1 NR 3 mo(s) NR Skin reaction 11
Cisplatin, epirubicin, and
interferon 
1 NR 26 mo(s) NR Skin reaction 11
Cyclophosphamide
7 g/wk  2 wk(s)
c 1 71 5 mo(s) Soon after
treatment
b Dermatitis, panniculitis,
and myositis
39
Cytarabine 9 g 1 20 9 mo(s) After 2nd dose Supraglottitis 40
Dacarbazine 800 mg/m
2 1 30 2 mo(s) 10 day(s) Skin reaction 41
Dactinomycin 4 10–60
b 6 day(s) to 7 mo(s)
b Soon after dose or Mild skin reaction (2) 42–45
(actinomycin D) 50–75
g/kg
b up to 55 day(s)
b Enteritis and bowel
obstruction (1)
Supraglottitis (1)
Daunorubicin
b 1 NR 6 mo(s) NR Skin reaction 11
Docetaxel 30–100 mg/m
2 12 30–70
b 1 wk to 6 yr(s) 3–14 day(s) after Skin reaction (8) 4, 9, 34,
1st to 3rd course Epiglottic ulceration and
mucositis (1)
36, 46–51
Skin reaction and
stomatitis (1)
Mucositis (2)
Docetaxel and epirubicin 2 NR 6 day(s)
d and NR Severe skin reaction (1) 6, 11
14 mo(s) Skin reaction and
vaginitis (1)
Doxorubicin 30–75 18 12–59.5
b 1 wk to 15 yr(s) Hours to 2 mo(s) or Skin reaction (10) 11, 14, 17,
mg/m
2 or 80 mg
b after 7th dose
(7 mo(s))
b Skin reaction and
mucositis with
ulceration (1)
43, 52–59
Ulcerative stomatitis (1)
Severe mucositis with
necrosis (1)
Pneumonitis (4)
Enteritis and bowel
obstruction (1)
Doxorubicin and cisplatin 1 NR 9 mo(s) NR Skin reaction 11
Edatrexate 100 mg/m
2
twice weekly
1 30 4 wk(s) 11 day(s) Skin reaction 60
Etoposide 100 mg/m
2  3
days
1 38 1 wk 18 hour(s) Mild-moderate skin
reaction
61
5-Fluorouracil 15
mg/kg  4 days
1 30 7 wk(s) 2 wk(s) Moderate skin reaction 62
5-Fluorouracil and
cisplatin
16 5 1m o
b 3 mo(s) after 2nd
course
Severe
lipodermatosclerosis
63
(continued)
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Drug
No. of
cases
Radiation
dose (Gy)
Time interval
between radiation
and chemotherapy
Time to onset
after
chemotherapy Reaction References
5-Fluorouracil, epirubicin,
and cyclophosphamide
1 NR 22 day(s) NR Moderate skin reaction 6
Gefitinib 250 mg/day 1 NR 2 mo(s) 6 wk(s) Pneumonitis 21
Gemcitabine 800-1250 17 24–60
b 1 wk to 2.5 yr(s)
b 2 day(s) to 6 mo(s)
b Skin reaction (6) 16, 64–75
mg/m
2b or gemcitabine-
based chemotherapy
Myositis  skin
reaction (7)
Lymphangitis (1)
Skin reaction, typhilitis,
and colitis (1)
Rectal myositis and
subcutaneous fat
stranding (1)
Optic neuritis (1)
Gemcitabine and
docetaxel
2 35 and 50.4 1 wk(s) and 8 mo(s) 25 day(s) and 7.75
mo(s)
Brainstem radionecrosis (1) 69, 76
Pneumonitis (1)
Gemcitabine and
vinorelbine
1 NR NR During 2nd cycle
b Skin reaction and
pneumonitis
77
Gemcitabine and
trastuzumab
1 30 6 mo(s) 2 wk(s) Mild skin reaction 78
Gemcitabine and
paclitaxel
12 0  2 10 day(s) 2 day(s) Skin reaction and
swelling in ear
37
Hydroxyurea 60 mg/kg
per day
4 16–30
b 7–47 day(s) 5–16 day(s) Skin reaction 79
Idarubicin 12 mg/m
2
per day
1 72–81 3 yr(s) 2 wk(s) Vulvitis and vaginal
necrosis
80
Interferon -2b 20 MU 1 30 5 day(s)
d 6 day(s) Skin reaction 81
Lomustine 1 9 mo(s) 24 hour(s) Supraglottitis 40
Melphalan 200 mg/m
2b 25 4
b 5–6 wk(s) 1 day
b Skin reaction 6, 82
Methotrexate 200 mg/kg
or 45 mg/m
2 2 16–30 3 and 8 wk(s) 5 and 7 day(s) Skin reaction 19, 83
Oxaliplatin
b 1 41.4 8 day(s) 3 day(s) Skin reaction 84
Paclitaxel 90–200 mg/m
2 6 25–50.4 1 wk to 13 mo(s) 3 hour(s) to Skin reaction (5) 18, 85–88
5 day(s) Dermatitis and
pneumonitis (1)
Paclitaxel and carboplatin 1 45 1 yr 1 day Colitis 89
Pemetrexed 500 mg/m
2b,e 2 NR 19 day(s) and 25
yr(s)
3 and 12 day(s) Skin reaction 15, 20
Tamoxifen 20 mg/day 4 50–64
b 1 wk(s) to 28
mo(s)
b,f 5 day(s) to 3 mo(s) Skin reaction 90–93
Vinblastine 0.2 mg/kg or
10 mg/m
2 2 27–56.44 2 and 10 mo(s) 1 and 2 day(s) Mild to moderate skin
reaction
94, 95
Vinorelbine and
trastuzumab
1 NR 12 day(s) NR Mild skin reaction 6
aBleeding did not recur when bevacizumab was discontinued, whereas gemcitabine was continued.
bInformation not provided on chemotherapy dosages, radiation dose, and/or time to onset in some reports.
cThe patient also received five cycles of vincristine, doxorubicin, and dexamethasone after radiotherapy and before
administration of cyclophosphamide. The reaction occurred immediately after cyclophosphamide treatment and the latter
was considered the causative drug.
dAlthough chemotherapy was initiated within 7 days of radiotherapy (outside the definition of radiation recall), this reaction
was considered radiation recall.
ePemetrexed was administered with cisplatin in one case, but radiation recall was attributed to pemetrexed.
fChemotherapy was initiated within 7 days of radiotherapy in one patient (outside the definition of radiation recall), but
the patient had no major skin reaction on completing radiotherapy and the reaction was considered radiation recall.
Abbreviations: bid, twice daily; mo, month; NR, not reported; wk, week; yr, year.
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as follows:
• Grade 1 (mild): Faint erythema or dry desquamation
• Grade 2 (moderate): Moderate to brisk erythema; patchy
moist desquamation, mostly confined to skin folds and
creases; moderate edema
• Grade 3 (severe): Moist desquamation other than skin
folds and creases; bleeding induced by minor trauma or
abrasion
• Grade 4 (life-threatening/disabling): Skin necrosis or ul-
ceration of full thickness dermis; spontaneous bleeding
from involved site
• Grade 5: Death
In about one third of cases, radiation recall reactions
may arise in sites of prior radiation therapy other than the
skin, including inflammatory reactions affecting the lungs,
oral mucosa, gastrointestinal system, genitourinary tract,
muscle layer, central nervous system, neck, and head, lead-
ing to possible functional impairment (Table 1). These ef-
fects may or may not occur in conjunction with cutaneous
lesions. Interestingly, radiation recall reactions with gem-
citabine appear to be predominantly noncutaneous, with
about two thirds of cases involving internal tissues and
organs [16] (Table 1).
AGENTS ASSOCIATED WITH RADIATION RECALL
Although radiation recall is not common, many of the most
widely used anticancer agents have been implicated in its
development (Table 1).
Chemotherapeutic agents reported to precipitate a radi-
ation recall reaction in patients who have previously re-
ceived radiation therapy include agents from most classes,
including alkylating agents, taxanes, anthracyclines, and
other antitumor antibiotics, antimetabolites, vinca alka-
loids,andtaxanes(Table1).Therangeofchemotherapeutic
drugs associated with the phenomenon is diverse and no
common features or characteristics of the drugs have been
identified. It is not clear whether radiation recall reactions
are a class effect or related to the drug dose or regimen. Re-
actions have occurred with a range of dosages of different
drugs (Table 1).
The development of radiation recall is drug-specific for
anyindividualpatient,anditisnotpossibletopredictwhich
patients will react to which drugs. A drug that causes radi-
ation recall in one patient may be able to be given safely to
another patient that has previously had a radiation recall re-
action to a different drug or vice versa. For instance, in a
patient with a previous radiation recall reaction to doxoru-
bicin,chemotherapywithvincristine,methotrexate,andcy-
clophosphamide was administered without reaction [17].
Radiation recall has been reported following treatment
with pemetrexed, paclitaxel, or methotrexate in patients
who have previously received other chemotherapy such
as gemcitabine, cyclophosphamide, epirubicin, and/or
doxorubicin without any reaction, although these agents
have been associated with radiation recall in other pa-
tients [15, 18, 19].
To date, the drugs for which radiation recall reactions
have been most commonly reported include the anthracy-
clinedoxorubicin,thetaxanesdocetaxelandpaclitaxel,and
theantimetabolitesgemcitabineandcapecitabine(Table1).
However, it must be kept in mind that because most data
come from case reports, and not all identified cases of radi-
ation recall will have been published, these trends may be
influencedbyreportingbiasandwilldependonhowwidely
used the drug is. For instance, it is only over recent years
that it has become evident that gemcitabine is one of the
drugs most commonly reported to be associated with radi-
ation recall reactions.
Radiation recall has also been reported with newer ther-
apies used in the treatment of various cancers including
pemetrexed [15, 20], gefitinib [21], trastuzumab in combi-
nation with vinorelbine [6], and bevacizumab in combina-
tion with gemcitabine [22]. It is notable that, in the case of
bevacizumab, the reaction was considered possibly related
to the new drug rather than gemcitabine; there was no re-
currence when gemcitabine monotherapy was continued
[22].
As an example of radiation recall with a new drug, we
present in detail a case study of a radiation recall reaction
induced by ixabepilone. This drug is the first of a new class
of antineoplastic agent, the epothilones, and thus there has
not previously been experience of radiation recall with this
drug class. The epothilones stabilize microtubule dynamics
leading to apoptotic cell death. The mechanism of action of
the epothilones is similar to, but distinct from, that of the
taxanes and the drug classes are not structurally related.
Ixabepilone is approved for the treatment of metastatic
breastcancerresistanttotaxanesandanthracyclines.Inthis
case, monotherapy with 40 mg/m
2 ixabepilone given 1
week after radiotherapy was associated with a skin reaction
and severe odynophagia in a 60-year-old woman with
breast cancer (see section “Case Study”). The patient’s ra-
diation oncologist classified the recall reaction as much
more severe (grade 3 as reported with second-degree burns
and blisters) than the primary radiation effects. It should be
noted that a patient completing a regimen of 30 Gy in 13
dayscouldverywellmanifestpureradiationtoxicity7days
later. In this case, late radiation esophagitis/dermatitis may
have been worsened because the patient was dosed with
ixabepiloneandtheresultinghospitalizationmayhavebeen
1232 Radiation Recall with Anticancer Agentsa result of overlapping radiation and chemotherapy toxici-
ties (palmar-plantar erythrodysesthesia).
Other drugs unrelated to cancer treatment have also
been implicated in the development of radiation recall. For
example, the antimicrobial/antibacterial agents gatifloxa-
cin [23], cefotetan [24], cefazolin [25], trimetrexate [26,
27], and levofloxacin [28], the nonsteroidal anti-inflamma-
tory agent, nimesulide [29], the lipid-lowering agent, sim-
vastatin [30], antitubercular drugs [31], the anorexiant,
phentermine [32], and the herbal medication, hypericin (St
John’s wort) [33]. Where stated, these events developed 8
months to 3 years after radiotherapy.
CASE STUDY
A 60-year-old white female was diagnosed with stage IIA
hormone receptor negative, HER-2 positive breast cancer
in 2001. The patient underwent partial mastectomy and
axilliary dissection followed by postoperative radiation
therapy and received adjuvant chemotherapy with cyclo-
phosphamide and doxorubicin, followed by single-agent
paclitaxel. Treatment was completed in April 2002. In late
2006,thepatientwasfoundtohavemetastaticdiseaseinthe
liver and lung. A liver biopsy confirmed adenocarcinoma
and the patient was treated with vinflunine plus trastu-
zumab under an experimental protocol. However, scanning
in March 2007 showed progressive liver disease. Vin-
flunine plus trastuzumab was discontinued and the patient
started on capecitabine plus lapatinib. This regimen was
tolerated well and the patient remained stable until Sep-
tember 2007 when a questionable new liver lesion was
detected.
Computed tomography scan in January 2008 confirmed
progressive disease and capecitabine plus lapatinib was
withdrawn. A magnetic resonance imaging scan revealed
multiple thoracic spine metastases. The patient received
palliativeradiotherapytotaling30.25GytoT6throughT12
and 27.50 Gy to T1 through T3 over 13 and 14 days, con-
currently.
One week later, she received chemotherapy with 40
mg/m
2 ixabepilone. When ixabepilone was initiated,
mild primary radiation effects were present (very slight
nonpainful erythema and mild odynophagia). On days 3
to 4 after ixabepilone, the patient developed increasing
erythema of her chest and increasing odynophagia. On
day 7, the patient was admitted to hospital for severe ab-
dominal pain, nausea, and vomiting, with associated
symptoms of fatigue, musculoskeletal pain, evidence of
palmar-plantar erythrodysesthesia, generalized oral ten-
derness but without overt mucositis/stomatitis, and che-
motherapy-induced leucopenia and thrombocytopenia.
Odynophagia had become severe.
Significantuponadmissionwasthepresenceofsecond-
degree burns to the patient’s chest that framed the two re-
cent radiation ports and was indicative of a radiation recall
reaction. The patient also showed a first-degree burn on her
back, which was more diffuse in pattern covering the tho-
racic spine. The abdominal pain in this patient was consid-
ered to be related to liver metastasis and/or cholelithiasis.
Treatment consisted of supportive and preventive care con-
sisting of IV fluids, antibiotics, pain control, promethazine,
topical oral clotrimazole, and topical silver sulfadiazine
cream and also nutritional and wound care. The patient re-
coveredwithoutinfectionandwasdischargedtohomeafter
10 days. Abdominal pain was ongoing and controlled with
narcotics.
Following the radiation recall reaction, the patient
chose to continue treatment, receiving two more cycles
of ixabepilone at a reduced dose of 20 mg/m
2 every 3
weeks with no further radiation effect observed. There
was a plan to increase her dose to 32 mg/m
2, but blood
counts did not safely allow for this. Unfortunately, after
the additional two cycles of therapy, computed tomogra-
phy scan demonstrated marked progression of metastatic
disease to the liver, and her performance status was de-
teriorating. The patient entered hospice care and died af-
ter a short time.
PREDICTING AND PREVENTING RADIATION RECALL
Radiation recall is unpredictable in nature. At present, it is
not possible to identify which patients will develop radia-
tion recall or design treatment regimens that will eliminate
its occurrence.
Although often occurring shortly after the first dose of
chemotherapy, radiation recall can also manifest after mul-
tiple courses of chemotherapy have been administered (Ta-
ble 1). When reaction recall occurs after subsequent rather
than the first dose, this may be indicative of a time lag for
the onset of the reaction rather than presensitization [3].
Most reports of radiation recall are in response to adminis-
tration of a single chemotherapeutic agent. However, there
is no evidence to suggest that combination chemotherapy
either increases or decreases the risk of radiation recall
compared with monotherapy [3].
Theredoesnotappeartobeaspecifictimewindowdur-
ing which there is an increased susceptibility to radiation
recall[6].However,risksmaybehigherwithashortertime
interval.IntheAmericanSocietyofBreastSurgeonsMam-
moSite Breast Brachytherapy Registry Trial, 9 of 50 (18%)
patients with breast cancer receiving chemotherapy 3
weeks after radiotherapy developed radiation recall, com-
pared with 6 of 81 (7.4%) patients receiving chemotherapy
3 weeks after radiotherapy (p  0.09) [7]. Radiation re-
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motherapy within 1 week of radiotherapy in this study;
however, reactions in this time frame are difficult to dif-
ferentiate from radiosensitization. It has also been re-
ported that radiation reactions tend to be more severe
when there is a shorter time between radiation and expo-
suretotheprecipitatingagents,butthisisnotadefinitive
association [1, 3, 4, 5]. Ultimately, it seems likely that
radiation recall occurs as a result of complex interplay
between the radiation regimen, the chemotherapy dose
and type, and timing.
It is not clear whether radiation recall reactions occur
more commonly when high-dose radiotherapy with
lower energy photon beams (6 MV) is applied [9]. In
twocaseswheredifferentradiationdoseswereappliedto
different areas of the body, radiation recall developed
only in the areas that had received the higher radiation
doses[34,35].However,suchassociationsarenotdefin-
itive, and no specific thresholds have yet been estab-
lished. For instance, in one of the latter cases radiation
recall occurred with doses 18.7 Gy, but in the other
cases radiation recall did not occur with 20 Gy [34, 35].
Other reports indicate that radiation recall has occurred
after radiation doses as low as 10 Gy (Table 1). The time
elapsed since radiation exposure may be a related com-
plicating factor; radiation recall reactions may be in-
duced after a lower radiation dose if the period between
chemotherapy and radiotherapy is relatively short [3].
MANAGEMENT OF RADIATION RECALL
Radiation recall is usually diagnosed through evaluation of
treatment history, symptoms, and physical examination.
Whereinternalorgansareaffected,assessmentmayinclude
radiologic studies. Biopsies are not normally necessary [2].
Treatmentdependsontheorgansystemaffectedandthe
severity of the reaction; however, no specific therapies are
available. Most instances resolve with optimal symptom
management. When the reaction is not severe, it may re-
solve spontaneously and an approach of close observation
is adequate. Supportive medical care may be needed when
internal organs are affected, and surgical intervention may
be necessary for severe cases [1, 2].
Theprecipitatingagentshouldbedelayedorwithdrawn
to allow the skin to heal. It is very rare for radiation recall
reactions to resolve whereas treatment with the implicated
drugiscontinued[3].Topicalorsystemiccorticosteroidsor
nonsteroidal anti-inflammatory drugs are sometimes used
to reduce inflammation. However, it is unclear whether ad-
ministration of corticosteroids speeds resolution compared
with the natural course of resolution after drug discontinu-
ation [3]. Antihistamines can also be used for symptomatic
relief.
Thetimeoverwhichradiationrecallresolvesappearsto
depend somewhat on the pharmacokinetics of the precipi-
tating agent, and reactions may resolve more rapidly after
discontinuation of intravenous treatment than oral treat-
ment. Reactions often resolve within days or 1 to 2 weeks,
althoughsometimesreactionstointravenousdrugsmayim-
prove within hours, whereas resolution may take over a
month for some oral drugs [3].
Rechallenge with a precipitating drug does not al-
wayselicitareaction.Whethersubsequentuseofthepre-
cipitating agent is appropriate depends on individual
circumstances, including patient preference and the ex-
tent, severity, and location of the reaction. The risk ver-
susbenefitbalanceandavailabilityofalternativeequally
effective agents must be considered. When the radiation
recall reaction is not severe, some patients may tolerate a
reduced dose or even the same dose of the precipitating
agent. Premedication with corticosteroids when rechal-
lenging may help prevent the inflammatory response, al-
though the value of this remains unproven [3, 36].
Although rechallenge has been possible without reaction
insomecases,inothercasesithasresultedinasimilaror
more severe reaction [1, 3, 37]. Camidge and Price re-
viewed 15 cases where rechallenge was attempted [3].
There was no recurrence of radiation recall in 5 patients
who received a reduced dose of the precipitating drug
and/or increased corticosteroid coverage. In 4 of the 10
patients with a recurring radiation recall, the reaction
upon drug rechallenge was less severe than the initial re-
action.
As with recently irritated skin, protection of the skin is
important and patients should be advised to stay out of the
sun, use sunscreens when exposure to the sun is unavoid-
able, avoid tanning beds, and wear loose, nonrestrictive
clothing.
CONCLUSIONS
Radiation recall, although usually of mild intensity, can
be severe and involve internal organs with possible func-
tional consequences. As radiotherapy and chemotherapy
arewidelyusedinconjunctiontotreatcancer,familiarity
withradiationrecallreactionsandtheirpotentialcompli-
cations may aid early diagnosis and appropriate manage-
ment.
There is still much that needs to be understood about
radiation recall, and it is not currently possible to predict
which patients will be affected and which drugs they will
reactto.Furthermore,therearenoidentifiablecharacter-
istics of drugs that cause radiation recall, and thus, it is a
1234 Radiation Recall with Anticancer Agentspossibilitythatmustbekeptinmindwithuseofanydrug
after radiotherapy, including those from new drug
classes. Although it is not yet possible to design treat-
ment regimens to eliminate the risk of radiation recall, it
seems likely that risks can be minimized by using the
lowest possible dose of radiation and prolonging the in-
terval between completion of radiotherapy and initiation
of chemotherapy.
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